EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The regulatory effects of PD-1/PD-L1 inhibitors on bone metabolism: opportunities and challenges in osteoporosis management

Jia-Wen Wang, Mu-Wei Dai, Jia-Hui Liu

Frontiers in Immunology · 2025

DOI: 10.3389/fimmu.2025.1630751 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Immunology, 2025. Verfasst von Jia-Wen Wang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, The Fourth Hospital of Hebei Medical University, 12 Health Road, Shijiazhuang, Hebei, China. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Osteoporosis, B7-H1 Antigen, Programmed Cell Death 1 Receptor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Programmed death-1 (PD-1) and its ligand PD-L1 inhibitors have become pivotal agents in cancer immunotherapy, demonstrating significant efficacy across multiple malignancies. However, beyond regulating T cell activation, the PD-1/PD-L1 axis also exerts complex and critical effects on bone metabolism. Notably, both clinical observations and mechanistic studies have revealed a paradox: on one hand, PD-1/PD-L1 blockade appears to confer bone-protective benefits; on the other hand, it has been associated with bone-related adverse events (AEs) in up to 69% of patients, including pathological fractures and vertebral compression fractures. This review comprehensively explores the bidirectional regulatory effects of the PD-1/PD-L1 pathway on bone metabolism and investigates the underlying mechanisms contributing to these contradictory findings. The discrepancies may be attributed to a combination of clinical variables, microenvironmental conditions, cell-specific responses, and intricate interactions among multiple signaling pathways, including the Wnt/β-Catenin pathway and the PD-L1–PKM2 axis. We further examine the pathophysiological basis of osteoporosis and fragility fractures occurring during PD-1/PD-L1 inhibitor therapy, and argue for their recognition as a subclass of immune-related adverse events (irAEs). Finally, we propose a framework for bone health surveillance and stratified prevention strategies aimed at preserving antitumor efficacy while improving skeletal health and quality of life—offering novel insights into osteoporosis prevention and management in the context of immune checkpoint inhibition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsOsteoporosisB7-H1 AntigenProgrammed Cell Death 1 ReceptorBone and BonesHumansAnimalsNeoplasms

Stichwörter der Autor:innen

PD-1/PD-L1 inhibitorsRANKLWnt signalingbone biomarkersbone metabolismimmune-related adverse eventsosteoblastsosteoclasts

Substanzen

Immune Checkpoint InhibitorsB7-H1 AntigenProgrammed Cell Death 1 ReceptorCD274 protein, humanPDCD1 protein, human

Autor:innen und Institutionen

  • Department of Orthopedics, The Fourth Hospital of Hebei Medical University, 12 Health Road, Shijiazhuang, Hebei, China.

Zitieren

APA

Wang, J. W., Dai, M. W., & Liu, J. H. (2025). The regulatory effects of PD-1/PD-L1 inhibitors on bone metabolism: opportunities and challenges in osteoporosis management. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2025.1630751

Vancouver

Wang JW, Dai MW, Liu JH. The regulatory effects of PD-1/PD-L1 inhibitors on bone metabolism: opportunities and challenges in osteoporosis management. Frontiers in Immunology. 2025. doi:10.3389/fimmu.2025.1630751

BibTeX
@article{Wang2025,
  author = {Wang, Jia-Wen and Dai, Mu-Wei and Liu, Jia-Hui},
  title = {The regulatory effects of PD-1/PD-L1 inhibitors on bone metabolism: opportunities and challenges in osteoporosis management},
  journal = {Frontiers in Immunology},
  year = {2025},
  doi = {10.3389/fimmu.2025.1630751}
}
Kostenlos starten →